22nd Apr 2009 07:00
Stock Exchange announcement
FOR release: 7.00am - Wednesday 22 April 2009
CELSIS INTERNATIONAL PLC
("Celsis", "the Company" or "the Group")
Appointment of Corporate Broker AND FINANCIAL ADVISER
22 April 2009: Celsis International plc, the life sciences products and laboratory services company, today announces the appointment of Nomura Code Securities Limited as its Corporate Broker and Financial Adviser with immediate effect.
Further information can be found on its website at www.celsis.com.
|
Enquiries: |
|
|
|
|
|
Celsis International plc |
Tel: 01223 598 428 |
|
Jay LeCoque |
|
|
Robyn LaLonde |
|
|
|
|
|
Nomura Code Securities |
Tel: 020 7776 1200 |
|
Chris Collins |
|
|
Phil Walker |
|
|
|
|
|
Financial Dynamics |
Tel: 020 7831 3113 |
|
Jonathan Birt |
|
|
Susan Quigley |
|
Notes to editors
Celsis International plc
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis business has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's leading pharmaceutical and consumer products companies. The Company is listed on the London Stock Exchange (CEL.L).
Celsis Rapid Detection utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market.
Celsis Analytical and Development Services provides cost effective outsourced laboratory testing services to pharmaceutical companies. Its comprehensive service offerings include a full spectrum of laboratory services from analytical chemistry and biological sciences to stability storage and testing.
Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical industry. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or research on those compounds that will not be properly metabolised by the human liver.
Related Shares:
Celadon Pharmaceuticals